Calcium, Probiotics and Acute Diarrheal Disease Among Indonesian Children - Full Text View

Purpose

This is a long term study on the efficacy of dietary calcium with or without probiotic strains in reducing the mean number of episodes and duration of diarrheal disease.

Condition	Intervention
Healthy Diarrhea	Dietary Supplement: low calcium milk of 180 ml Dietary Supplement: regular milk of 180 ml Dietary Supplement: regular milk of 180 ml + probiotics


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Prevention
Official Title:	Calcium, Probiotics and Acute Diarrheal Disease Among Indonesian Children Aged 1-6 Years in Low Socio-economic Urban Area of East Jakarta

Resource links provided by NLM:

MedlinePlus related topics: Calcium

Drug Information available for: Calcium Gluconate

U.S. FDA Resources

Further study details as provided by Wageningen University:

Primary Outcome Measures:

The mean number of episodes and duration of acute diarrheal disease [ Time Frame: 24 weeks ]

Secondary Outcome Measures:

Incidence of acute diarrheal disease [ Time Frame: 24 weeks ]
Severity of acute diarrheal disease [ Time Frame: 24 weeks ]
Intestinal and systemic inflammation [ Time Frame: 24 weeks ]
Intestinal colonization with pathogenic bacteria or viruses [ Time Frame: 24 weeks ]
Nutritional status based on anthropometric measurement [ Time Frame: 24 weeks ]
Iron and zinc status [ Time Frame: 24 weeks ]
Incidence, mean episodes and duration of acute respiratory infections [ Time Frame: 24 weeks ]


Enrollment:	494
Study Start Date:	August 2007
Study Completion Date:	September 2008
Primary Completion Date:	September 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: 1	Dietary Supplement: low calcium milk of 180 ml twice daily for 24 weeks
Active Comparator: 2	Dietary Supplement: regular milk of 180 ml twice daily for 24 weeks
Active Comparator: 3	Dietary Supplement: regular milk of 180 ml + probiotics twice daily for 24 weeks
Active Comparator: 4	Dietary Supplement: regular milk of 180 ml + probiotics twice daily for 24 weeks

Eligibility


Ages Eligible for Study:	1 Year to 6 Years (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Apparently healthy children aged 1-6 years, with emphasize on aged 2-5 years, living permanently in low socio-economic urban areas of East Jakarta for at least 6 months
Parents are willing to sign the informed consent and give the supplements to the children for the period of 6 months
Capable and willing to drink liquid milk with a straw (acceptance to be tested at screening by providing a sample drink and placebo straw to be consumed under supervision for 2 days)

Exclusion Criteria:

Calcium intake exceeding 75% of the RDA for calcium (<375 mg/d) based on a Food Frequency Questionnaire
Currently breastfed children
Siblings of already included children that are living in the same household, except if it is a twin sibling
Severely malnourished with or without oedema (Weight for height-WHZ Z-score of <-3.00 SD)
Symptoms of chronic/congenital diseases and disabilities, suspected Tuberculosis by clinical examination, and /or history of allergic disease.
Taking (any) antibiotics during 2 weeks prior to start of the study (children will be included after 3 weeks of last antibiotic intake
Participation in another clinical trial at the same time or 2 months prior to the start of this study
Both mothers and other caregivers present in the family are illiterate

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00512824

Locations


Indonesia
Seameo-Tropmed Rccn Ui
Jakarta, Indonesia, 10430

Sponsors and Collaborators

Wageningen University

Top Institute Food and Nutrition

Indonesia University

Investigators


Principal Investigator:	Rina Agustina, MD	SEAMEO-TROPMED RCCN UI
Study Chair:	Frans J. Kok, Prof	Division of Human Nutrition, Wageningen University (WUR)
Study Director:	Ingeborg Bovee-Oudenhoven, PhD	TIFN/ NIZO Food Research
Study Chair:	Agus Firmansyah, Prof, MD	Faculty of Medicine University of Indonesia
Study Director:	Widjaja Lukito, MD	SEAMEO-TROPMED RCCN UI

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Agustina R, Bovee-Oudenhoven IM, Lukito W, Fahmida U, van de Rest O, Zimmermann MB, Firmansyah A, Wulanti R, Albers R, van den Heuvel EG, Kok FJ. Probiotics Lactobacillus reuteri DSM 17938 and Lactobacillus casei CRL 431 modestly increase growth, but not iron and zinc status, among Indonesian children aged 1-6 years. J Nutr. 2013 Jul;143(7):1184-93. doi: 10.3945/jn.112.166397. Epub 2013 May 22.

Agustina R, Kok FJ, van de Rest O, Fahmida U, Firmansyah A, Lukito W, Feskens EJ, van den Heuvel EG, Albers R, Bovee-Oudenhoven IM. Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children. Pediatrics. 2012 May;129(5):e1155-64. doi: 10.1542/peds.2011-1379. Epub 2012 Apr 9.


Responsible Party:	Ingeborg Bovee-Oudenhoven, Top Institute Food and Nutrition
ClinicalTrials.gov Identifier:	NCT00512824 History of Changes
Other Study ID Numbers:	A011-CPDI
Study First Received:	August 6, 2007
Last Updated:	January 7, 2011

Keywords provided by Wageningen University:


calcium probiotics diarrhea children	Indonesia Healthy children acute diarrhea

Additional relevant MeSH terms:


Diarrhea Signs and Symptoms, Digestive Signs and Symptoms Calcium, Dietary Calcium Carbonate	Bone Density Conservation Agents Physiological Effects of Drugs Antacids Molecular Mechanisms of Pharmacological Action Gastrointestinal Agents

ClinicalTrials.gov processed this record on July 27, 2017